For more than 6 years now, Syncrosome has worked as a preclinical CRO accredited by the French Ministry of Higher Education and Research for Research Tax Credits (CIR).
Our recognition procures a significant financial benefit for French companies wishing to pursue their R & D work in Cardiovascular, Central Nervous System, Respiratory or Gastrointestinal field with Syncrosome.
This authorization is accorded for the years 2015 to 2019.
A few words about Syncrosome:
Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.
We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.
Our main activities consit in :
- Drug Efficacy Studies in several therapeutic areas :
- Central Nervous Sytem,
- Cardiovascular and Metabolic disease,
- Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.